Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 152

1.

Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma.

Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr.

Blood. 2005 Jul 1;106(1):296-303. Epub 2005 Mar 8.

2.

Molecular pathogenesis and a consequent classification of multiple myeloma.

Bergsagel PL, Kuehl WM.

J Clin Oncol. 2005 Sep 10;23(26):6333-8. Review.

PMID:
16155016
3.

Advances in biology of multiple myeloma: clinical applications.

Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC.

Blood. 2004 Aug 1;104(3):607-18. Epub 2004 Apr 15. Review.

4.

Early genetic events provide the basis for a clinical classification of multiple myeloma.

Kuehl WM, Bergsagel PL.

Hematology Am Soc Hematol Educ Program. 2005:346-52.

PMID:
16304402
5.

Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma.

Bergsagel PL, Kuehl WM.

Immunol Rev. 2003 Aug;194:96-104. Review.

PMID:
12846810
6.

Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma.

Shaughnessy J Jr, Gabrea A, Qi Y, Brents L, Zhan F, Tian E, Sawyer J, Barlogie B, Bergsagel PL, Kuehl M.

Blood. 2001 Jul 1;98(1):217-23.

7.

Post-transcriptional Modifications Contribute to the Upregulation of Cyclin D2 in Multiple Myeloma.

Misiewicz-Krzeminska I, Sarasquete ME, Vicente-Dueñas C, Krzeminski P, Wiktorska K, Corchete LA, Quwaider D, Rojas EA, Corral R, Martín AA, Escalante F, Bárez A, García JL, Sánchez-García I, García-Sanz R, San Miguel JF, Gutiérrez NC.

Clin Cancer Res. 2016 Jan 1;22(1):207-17. doi: 10.1158/1078-0432.CCR-14-2796. Epub 2015 Sep 4.

8.

[Molecular Mechanism and Malignant Clonal Evolution of Multiple Myeloma].

Ding F, Zhu P, Wu XQ.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015 Oct;23(5):1513-6. doi: 10.7534/j.issn.1009-2137.2015.05.056. Chinese.

PMID:
26524068
9.

Chromosome translocations in multiple myeloma.

Bergsagel PL, Kuehl WM.

Oncogene. 2001 Sep 10;20(40):5611-22. Review.

10.

Distinguishing primary and secondary translocations in multiple myeloma.

Gabrea A, Leif Bergsagel P, Michael Kuehl W.

DNA Repair (Amst). 2006 Sep 8;5(9-10):1225-33. Epub 2006 Jul 10. Review.

PMID:
16829212
11.

Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses.

Fabris S, Agnelli L, Mattioli M, Baldini L, Ronchetti D, Morabito F, Verdelli D, Nobili L, Intini D, Callea V, Stelitano C, Lombardi L, Neri A.

Genes Chromosomes Cancer. 2005 Feb;42(2):117-27.

PMID:
15543617
12.

Frequency and distribution of trisomy 11 in multiple myeloma patients: relation with overexpression of CCND1 and t(11;14).

Guglielmelli T, Giugliano E, Cappia S, Papotti M, Saglio G.

Cancer Genet Cytogenet. 2007 Feb;173(1):51-6.

PMID:
17284370
13.

Protein Expression for Novel Prognostic Markers (Cyclins D1, D2, D3, B1, B2, ITGβ7, FGFR3, PAX5) Correlate With Previously Reported Gene Expression Profile Patterns in Plasma Cell Myeloma.

Mansoor A, Akhter A, Pournazari P, Mahe E, Shariff S, Farooq F, Elyamany G, Shahbani-Rad MT, Rashid-Kolvear F.

Appl Immunohistochem Mol Morphol. 2015 May-Jun;23(5):327-33. doi: 10.1097/PAI.0000000000000089.

PMID:
25265432
14.

Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling.

Fu K, Weisenburger DD, Greiner TC, Dave S, Wright G, Rosenwald A, Chiorazzi M, Iqbal J, Gesk S, Siebert R, De Jong D, Jaffe ES, Wilson WH, Delabie J, Ott G, Dave BJ, Sanger WG, Smith LM, Rimsza L, Braziel RM, Müller-Hermelink HK, Campo E, Gascoyne RD, Staudt LM, Chan WC; Lymphoma/Leukemia Molecular Profiling Project.

Blood. 2005 Dec 15;106(13):4315-21. Epub 2005 Aug 25.

15.

Frequent occurrence of CCND1 deregulation in patients with early stages of plasma cell dyscrasia.

Miura K, Iida S, Hanamura I, Kato M, Banno S, Ishida T, Kusumoto S, Takeuchi G, Miwa H, Nitta M, Inagaki H, Eimoto T, Nomura K, Taniwaki M, Ueda R.

Cancer Sci. 2003 Apr;94(4):350-4.

16.

Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma.

Mattioli M, Agnelli L, Fabris S, Baldini L, Morabito F, Bicciato S, Verdelli D, Intini D, Nobili L, Cro L, Pruneri G, Callea V, Stelitano C, Maiolo AT, Lombardi L, Neri A.

Oncogene. 2005 Apr 7;24(15):2461-73.

PMID:
15735737
17.

Deregulation of cyclin D2 by juxtaposition with T-cell receptor alpha/delta locus in t(12;14)(p13;q11)-positive childhood T-cell acute lymphoblastic leukemia.

Karrman K, Andersson A, Björgvinsdóttir H, Strömbeck B, Lassen C, Olofsson T, Nguyen-Khac F, Berger R, Bernard O, Fioretos T, Johansson B.

Eur J Haematol. 2006 Jul;77(1):27-34. Epub 2006 Mar 17.

PMID:
16548914
18.

Cyclin D1 positive multiple myeloma: predominance of the short, 3'UTR-deficient transcript is associated with high cyclin D1 mRNA levels in cases with t(11;14) translocation, but does not correlate with proliferation rate or genomic deletions.

Slotta-Huspenina J, Koch I, Richter M, Bink K, Kremer M, Specht K, Krugmann J, Quintanilla-Martinez L, Fend F.

Leuk Res. 2008 Jan;32(1):79-88. Epub 2007 Jul 16.

PMID:
17629555
19.

Close relation between 14q32/IGH translocations and chromosome 13 abnormalities in multiple myeloma: a high incidence of 11q13/CCND1 and 16q23/MAF.

Takimoto M, Ogawa K, Kato Y, Saito T, Suzuki T, Irei M, Shibuya Y, Suzuki Y, Kato M, Inoue Y, Takahashi M, Sugimori H, Miura I.

Int J Hematol. 2008 Apr;87(3):260-5. doi: 10.1007/s12185-008-0039-x. Epub 2008 Feb 16.

PMID:
18274833
20.

Amplification and expression of cyclin D genes (CCND1, CCND2 and CCND3) in human malignant gliomas.

Büschges R, Weber RG, Actor B, Lichter P, Collins VP, Reifenberger G.

Brain Pathol. 1999 Jul;9(3):435-42; discussion 432-3.

PMID:
10416984

Supplemental Content

Support Center